CureVac (NASDAQ: CVAC) is working on mRNA coronavirus vaccine candidates. If it’s successful, mRNA vaccine giants Moderna and Pfizer will face competition. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss whether investors should buy CureVac shares as a way to invest in this game-changing technology.
10 stocks we like better than CureVac
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and CureVac wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of June 7, 2021
Olivia Zitkus: How do you feel about it as an mRNA bet? People talk about Moderna as a bet on mRNA for the rest of their pipeline. What do you think about CureVac? Like you’ve mentioned, once they have the technology in place, it’s a lot easier to set up a new vaccine to change the code — I’ll use that language — and instruct the body to produce something slightly different for maybe a different variant of the coronavirus or a different virus or disease altogether. What do you think about this mRNA bet, purely?
Adria Cimino: Well, I think right now it’s still risky because Moderna has shown, “Hey, we can do this.” So now let’s apply it to lots of different areas. CureVac, because of this data, they’re going to have to show us that they can do it. They’re going to have to show better data I think before we can say, OK. Right now, it’s maybe a bet for very aggressive investors because they figure, well, hey, I can get it at a very good price, and I will make a small position in this whereas Moderna has gone up quite a bit. But I would feel a little bit… definitely more confident investing right now in Moderna, because they’ve proven that they can do this, and they’ve got the data behind it and everything. Right now, CureVac is still pretty risky.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.